Antimicrobial Resistance: Drug Pipeline Status and Global Mortality Projections

Executive Summary

The WHO's 2025 Global Antimicrobial Resistance and Use Surveillance System (GLASS) report confirms that resistance among Gram-negative bacterial pathogens, including E. coli, K. pneumoniae, and Acinetobacter, is rising, with resistance increasing in 40% of pathogen-antibiotic combinations monitored between 2018 and 2023. The threat is not evenly distributed: resistance rates for bloodstream infections reached 41.2% in the WHO South-East Asia Region, compared with 16.7% globally, while urinary tract infection resistance stood at 31.1% in South-East Asia versus 10.9% globally. Against this backdrop, the pharmaceutical pipeline is showing meaningful, if insufficient, movement: on June 17, 2026, the FDA approved tebipenem pivoxil (Utebzi) for complicated urinary tract infections, making it the first and only oral carbapenem antibiotic approved in the US. For corporate risk managers and health-system planners, the interplay between accelerating resistance and a thin but improving treatment pipeline defines the near-term strategic terrain.

The Regional Fault Lines: Where Resistance Is Winning

Roughly one in six bacterial infections worldwide involves antibiotic-resistant pathogens, rising to one in three for urinary tract infections. Resistance to fluoroquinolones and third-generation cephalosporins exceeds 40-70% for E. coli and Klebsiella pneumoniae in many regions. That aggregate figure, however, conceals a stark north-south divide that has direct implications for supply chains, health-system risk, and pharmaceutical market strategy.

The WHO's Yvan Hutin, director of the AMR department, stated at a press briefing that "antibiotic resistance is not only widespread and increasing, but it's also unevenly distributed across the globe." The CIDRAP reporting of WHO surveillance data confirms that resistance trends differ sharply across pathogens, antibiotics, and geographic regions, a fact that aggregate global figures consistently obscure. In the WHO South-East Asian and Eastern Mediterranean regions, an estimated one in three common bacterial infections are now drug-resistant, compared with only one in ten in Europe. Africa sits at approximately one in five.

These regional dynamics compound existing economic and security uncertainty. In South Asia and Sub-Saharan Africa, where AMR disproportionately burdens low- and middle-income countries with fragile health systems, inadequate laboratories, and restricted access to effective antibiotics, the result is a feedback loop: resistance rises, treatment options narrow, healthcare costs climb, and workforce productivity falls. This spillover affects multiple sectors, from agricultural competitiveness (antibiotic overuse in livestock farming accelerates environmental resistance gene spread) to the attractiveness of manufacturing investment in regions where workforce health is a variable input cost. A review published in Nature examined how bacterial communities and antibiotic resistance profiles shift even in marine environments near industrial farming operations, confirming that AMR is not contained within hospital walls.

The surveillance gap itself is a strategic risk. Regional gaps persist particularly in Africa, the Americas, and parts of Asia, where surveillance infrastructure remains limited, meaning investment decisions and supply-chain risk assessments built on GLASS data are working from an incomplete map. The London School of Hygiene and Tropical Medicine's Professor Gwen Knight noted in her review of the 2025 GLASS report that the Bayesian modelling now used by WHO attempts to correct for surveillance bias, but acknowledged that "critical surveillance gaps" remain in underrepresented regions.

Why The Pipeline Is Structurally Thin, And What Is Changing

The antimicrobial pipeline problem is not a failure of science. It is a failure of incentive architecture. Antibiotics are taken for short courses, are often priced cheaply to encourage access, and face immediate stewardship pressure to restrict use once approved, precisely the opposite of commercial conditions that attract sustained pharmaceutical investment. The WHO's own fact sheet notes that zoliflodacin and gepotidacin are among just seven approved and late-stage products highlighted in the Access to Medicine Foundation's 2026 AMR Benchmark Report, which evaluates efforts of pharmaceutical companies involved in antibiotic development, including candidates for resistant Gram-negative bacteria and multidrug-resistant tuberculosis.

The structural picture has not fundamentally changed: most major pharmaceutical companies exited antibiotic R&D in the 1990s and 2000s, and the pipeline has been sustained largely by small biotechs and public-private partnerships. A 2025 review of FDA-approved antibacterials published in academic journals confirmed that, since 1955, only a limited cohort of peptide-based antimicrobial drugs has received FDA approval.

What is changing is at the margins, and the margins matter. Three developments in 2025-2026 deserve attention:

First, the oral carbapenem milestone. The FDA approved Utebzi (tebipenem pivoxil) on June 17, 2026, making it the first and only oral carbapenem antibiotic approved in the US, supported by the Phase 3 PIVOT-PO trial demonstrating non-inferiority to intravenous imipenem-cilastatin. GSK's Chief Scientific Officer Tony Wood framed the approval explicitly in AMR terms: "With antibiotic resistance continuing to rise, patients and health care professionals need new treatment options." The broader healthcare system implication is significant: previously, patients with resistant complicated UTIs requiring carbapenem therapy had to be hospitalized for intravenous antibiotics or managed via costly infusion centers, and an oral carbapenem reduces that strain on the healthcare system.

Second, the gonorrhea treatment breakthrough. The Access to Medicine Foundation's 2026 AMR Benchmark Report highlighted that zoliflodacin and gepotidacin represent the first new oral treatment options for gonorrhea in decades. The two drugs arrived at a time when gonorrhea cases are rising and current treatment options are becoming less effective, a convergence of epidemiological and pharmaceutical timing that makes the approvals practically significant rather than merely incremental.

Third, the antifungal pipeline acceleration. The interplay between agricultural azole fungicide use and clinical azole resistance in Aspergillus fumigatus has created a resistance mechanism that emerged outside hospitals, making it harder to contain. Olorofim, from F2G and Shionogi, operates via a novel mechanism, inhibiting dihydroorotate dehydrogenase, that is entirely distinct from existing azole and echinocandin classes, addressing the cross-resistance problem directly. Phase III OASIS data released in June 2026 show non-inferiority for invasive aspergillosis patients who are refractory or unsuitable for azole therapy, positioning the drug for regulatory submission.

The Structural Economic Pressure That Will Force Policy Action

The economic case for AMR intervention has historically failed to generate the urgency it deserves because the costs are diffuse, long-dated, and concentrated in countries with limited lobbying power in multilateral institutions. That picture is shifting as healthcare systems in middle-income countries, Brazil, India, Mexico, South Africa, begin absorbing costs that were previously externalized onto individual patients. The Center for Global Development estimates that the impact of antimicrobial resistance falls most heavily on low- and lower-middle-income countries, and that AMR currently increases global healthcare costs by $66 billion annually, projected to rise to $159 billion under business-as-usual resistance trajectory assumptions.

Taken together, these developments are mutually reinforcing: the economic pressure from rising AMR is beginning to create political will for structural reform of the antibiotic market, even as the pharmaceutical pipeline, while improved, remains insufficient to address the Gram-negative bacterial threat that GLASS identifies as the most urgent clinical problem. The WHO's 2025 policy agenda explicitly calls for all nations to increase the share of "Access" antibiotics to at least 70% of total human use, and to expand diagnostic and laboratory capacity so at least 80% of countries can test all GLASS pathogens by 2030, targets that, if achieved, would themselves reduce selection pressure for resistance.

The World Health Assembly adopted an updated Global Action Plan on Antimicrobial Resistance covering 2026-2036 in May 2026, signalling institutional commitment at the highest level. Whether that commitment translates into the pull incentive mechanisms, subscription models, transferable exclusivity vouchers, guaranteed market commitments, that most economists argue are necessary to restart large-pharma antibiotic R&D remains the central open question.

Securitization Theory Analysis

Securitizing Actors: The WHO, national health ministries, and multilateral bodies including the G7 and G20 are the primary frames. The WHO's Director-General and regional directors have consistently invoked existential language around AMR, and the 2026 World Health Assembly adoption of the updated Global Action Plan formalizes the securitization attempt at the highest institutional level.

Referent Object: Human health broadly, specifically the continued effectiveness of modern medicine. The WHO has framed AMR as a threat not merely to individual patients but to the foundations of surgical care, cancer treatment, and maternal health, all of which depend on functional antibiotics for infection prophylaxis.

Existential Threat Construction: The WHO's 2025 GLASS report frames AMR as "compromising the effectiveness of life-saving treatments, posing a serious, growing threat to global health and undermining the foundations of modern medicine." Academic literature reinforces this with projections of tens of millions of deaths by 2050 under business-as-usual scenarios. The "post-antibiotic era" framing, explicitly invoked in veterinary and agricultural AMR literature, constructs the threat as civilizational rather than merely clinical.

Target Audience: Primarily national governments (to fund surveillance and stewardship programs) and pharmaceutical companies (to re-enter antibiotic R&D). A secondary audience is the general public, mobilized through "superbug" framing in media coverage.

Extraordinary Measures: National action plans on AMR, the WHO's push-pull incentive frameworks, legislated antibiotic subscription models piloted in the UK and Sweden, and the May 2026 World Health Assembly adoption of the updated Global Action Plan represent measures that go beyond normal market or regulatory processes.

Classification: SECURITIZED

AMR has crossed into securitized territory at the multilateral institutional level, with the World Health Assembly formalizing the extraordinary-measures framework in May 2026. Whether securitization is accepted by the full target audience, particularly large pharmaceutical companies and governments in the Global South, remains contested.

Process Tracing Analysis

Cause and Outcome: The cause is the systematic overuse and misuse of antimicrobials in human medicine, agriculture, and animal husbandry. The outcome is increasing prevalence of resistant bacterial and fungal pathogens in clinical settings, particularly in low- and middle-income countries.

Causal Mechanism Chain: (1) Antimicrobials are applied at sub-therapeutic doses or for inappropriate indications, creating selective pressure. (2) Bacteria with naturally occurring resistance genes survive and reproduce, while susceptible strains are killed, Darwinian selection operating at accelerated speed due to bacterial generation times. (3) Resistance genes are transferred horizontally between bacterial species via plasmids, accelerating spread beyond the original host species and geographic location. The Quest Diagnostics and Center for Disease Dynamics study identified the CTX-M-15 gene as a primary vector that "has spread to hundreds of strains, bringing with it not only antibiotic-resistance traits but also tolerance for stress and metal exposure." (4) Resistant organisms circulate in healthcare settings, community environments, and agricultural runoff, seeding new resistance across populations. (5) Clinical treatment fails; patients require more expensive second- and third-line agents or die.

Evidence Assessment:

• Smoking gun: Laboratory confirmation of resistance gene transfer via plasmids across species in clinical isolates, multiple peer-reviewed studies including the Nature Chile salmon farming study confirming horizontal gene transfer in marine environments adjacent to industrial aquaculture.
• Hoop test: Rising resistance rates in countries with documented high antibiotic consumption, GLASS data confirms this link must be present for the causal story to hold, and it is.
• Straw-in-the-wind: Regional variation in resistance rates correlating with antibiotic use patterns, consistent with the mechanism but explainable by alternative confounders including healthcare system quality.

CAUSAL_MECHANISM_STRENGTH: STRONG

Constructivism Lens Analysis

Actor Identities: The WHO projects the identity of "norm entrepreneur" and global health guardian. Pharmaceutical companies are positioned, by WHO and civil society framing, as potential "responsible innovators" but have largely adopted the identity of rational market actors constrained by broken incentive structures. Low- and middle-income country governments oscillate between "victim" framing and "sovereignty" framing when AMR stewardship requirements conflict with agricultural export interests.

Operative Norms: The "One Health" framework, which the WHO, FAO, and the World Organisation for Animal Health jointly developed, represents an operative norm that defines responsible antimicrobial stewardship as necessarily spanning human, animal, and environmental health simultaneously. This norm enables sweeping policy demands but also creates friction with agricultural sectors that resist regulatory intrusion.

Intersubjective Meaning: The dominant narrative, "post-antibiotic apocalypse" versus "manageable public health challenge", remains contested between high-income and low-income country actors. For low-income country governments, access to antibiotics is itself a development right; restrictions framed as stewardship can read as rich-country paternalism. This ideational cleavage explains why national AMR action plans, required under WHO's Global Action Plan, vary dramatically in ambition and implementation.

Norm Lifecycle Stage: The One Health and AMR stewardship norms have reached the cascade stage in high-income countries, most have national action plans and antibiotic consumption reporting systems. In low- and middle-income countries, the norms are still in the emerging-to-cascade transition, with implementation lagging behind formal adoption.

Norm Lifecycle: CASCADE (in high-income countries); EMERGING (across much of the Global South)

Counterarguments

1. The resistance trend may be self-limiting in high-income countries through stewardship effects, undermining the universalized alarm: Several European countries, the Netherlands, Sweden, Denmark, have maintained low resistance rates for key pathogens over extended periods through aggressive stewardship. The European Antimicrobial Resistance Surveillance Network (EARS-Net) data shows that the north-south gradient within Europe is partially explained by differences in antibiotic prescribing culture and regulation. If stewardship works in high-income settings, the global crisis narrative may conflate a truly severe trajectory in LMICs with a manageable trajectory elsewhere. The policy implication, that resource allocation should be heavily concentrated on low-income country capacity-building rather than on incentivizing new antibiotic development for high-income markets, differs substantially from the current multilateral agenda.

2. The "thin pipeline" framing may undercount innovation occurring in non-Western pharmaceutical ecosystems: The Access to Medicine Foundation's 2026 AMR Benchmark Report evaluates 25 companies, the majority headquartered in the US and Europe. Chinese and Indian pharmaceutical companies, operating under different regulatory frameworks and with substantial domestic resistance burdens, have approvals and late-stage candidates that receive limited coverage in Western-facing surveillance frameworks. A purely OECD-centric pipeline assessment may structurally undercount available innovation, particularly for Gram-negative pathogens where Asian-market approvals have outpaced FDA/EMA-market approvals. This does not resolve the access and affordability problem, but it complicates the narrative that the pipeline is uniformly barren.

3. The economic cost projections carry structural model uncertainty that may be driving policy overreaction in some settings and underreaction in others: The World Bank's GDP loss projections for AMR range from $1 trillion to $3.4 trillion annually by 2030, a spread wide enough to support almost any policy priority. The Center for Global Development's bottom-up estimate of $66 billion in current annual healthcare costs is derived from a specific cost-of-treatment model that assumes baseline treatment costs and resistance-attributable incremental spending can be cleanly separated, an assumption that critics argue overstates the precision of the estimate. If the actual economic burden is toward the lower end of the range, some of the urgency framing, particularly around diverting public funds from competing health priorities in LMICs, may be premature.

Indicators To Watch

Decision Relevance

Scenario A (~55%): Continued incremental progress, resistance rises but new approvals and stewardship partially offset trend, The current trajectory continues: 2-4 new antimicrobial approvals per year address specific resistance gaps, GLASS surveillance expands modestly, and high-income countries maintain manageable resistance rates while LMICs continue to bear disproportionate burden. Recommended: For healthcare investors, GSK's growing anti-infectives portfolio (Utebzi, Blujepa/gepotidacin, zoliflodacin) represents a rare established-company bet on the space; monitor for commercial uptake data in late 2026. For supply-chain risk managers, model second-supplier options for operations in South-East Asia and South Asia where treatment failure rates for common infections now exceed 30%.

Scenario B (~30%): Pipeline acceleration triggered by pull incentive breakthrough, The May 2026 Global Action Plan adoption catalyses binding pull incentive commitments from G7 governments, modelled on the UK's subscription pilot, that bring two to three major pharmaceutical companies back into antibiotic R&D within three to five years. This would improve the medium-term pipeline but offer no relief on the 5-7 year clinical development timelines for drugs not yet in Phase II. Recommended: Monitor parliamentary/legislative progress in the US (PASTEUR Act or equivalent) and EU member states. Position for a modest re-rating of small-cap AMR-focused biotechs if concrete public funding commitments materialise before year-end 2026.

Scenario C (~15%): Acceleration of resistance in a critical pathogen outpaces clinical response capacity, A carbapenem-resistant Klebsiella pneumoniae or Acinetobacter baumannii strain with pan-resistance spreads across multiple WHO regions simultaneously, triggering WHO emergency status and forcing emergency use authorisations for investigational agents. This scenario is not hypothetical in structure, it has occurred in limited geographic contexts, but broad simultaneous multi-regional spread has not yet been documented. Recommended: Healthcare procurement officers should audit current formulary coverage for pan-resistant Gram-negatives; hospitals with high-acuity surgical and oncology units are the highest-risk settings and should have contingency protocols in place now.

Analytical Limitations

• The 2025 GLASS report's most recent clinical data covers 2023 infections; a two-to-three year lag in surveillance data means that any resistance accelerations driven by post-COVID antibiotic overuse patterns in 2024-2025 are not yet visible in the primary surveillance base used for this assessment.
• Regional resistance estimates for Sub-Saharan Africa and parts of South Asia are modelled rather than directly measured; the Bayesian corrections applied by WHO improve comparability but cannot substitute for actual laboratory data from countries that have not yet built sufficient testing infrastructure.
• The pharmaceutical pipeline data available publicly reflects FDA/EMA-registered trials and approvals; drugs in development through Chinese NMPA, Indian CDSCO, and other national regulatory pathways are incompletely captured, which may cause this assessment to understate available innovation in specific drug classes.
• Economic burden projections (World Bank, Center for Global Development) carry wide confidence intervals that reflect genuine model uncertainty rather than false precision; the range between best-case and worst-case scenarios is an order of magnitude, limiting the utility of these figures for specific investment decisions.
• Antifungal resistance data quality is substantially weaker than antibacterial data; fungal surveillance systems are nascent in most LMICs, and the full scope of azole-resistant Aspergillus spread from agricultural environments into clinical settings remains incompletely mapped.